ArticleVirchows Archiv : an international journal of pathology2026
Identifying hormone receptor-positive breast cancer subtypes with recurrence scores derived from pathological data without Ki-67 indices: a clinicopathological study of breast cancer survival in West Asia.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) consists of several subtypes that vary regionally by incidence and mortality rates. The study population consisted of 1411 incident BCs diagnosed in Sulaimania, Iraq, in the years 2009-2014. Based upon positive (p) or negative (n) reactions, hormone receptor (HR)pHER2n tumors were divided into low recurrence risk (HRp low-risk) and high recurrence risk (HRp high-risk) subtypes with the Magee 2 equation that uses pathological data, without a Ki67 index. The 5-, 10-, and 13-year distant disease-free survival (DDFS) rates for the subtypes were estimated using proportional hazards models. The median age of patients for all subtypes was < 50 years. The proportion of subtypes was 29.6% for HRp low-risk, 36.2% for HRp high-risk, 11.8% for HRpHER2p, 11.7% for HRnHERp, and 10.6% for triple-negative (TN) BC. The 5-, 10-, and 13-year DDFS rates were as follows: HRp low-risk (n = 418, 85.5%, 74.4%, 71.7%), HRp high-risk (n = 511, 76.2%, 62.8%, 58.7%), HRpHER2p (n = 167; 77.7%, 58.6%, not reached), HRnHER2p (n = 165; 60.4%, 46.6%, not reached), and TNBC (n = 150; 61.4%, 54.2%, not reached). The difference in DDFS between HRp low-risk vs HRp high-risk was significant, p < 0.001, as were the differences between HRp high-risk vs HRnHER2p and HRp high-risk vs TNBC, both p < 0.001. The difference in DDFS between HRp high-risk vs HRpHER2p BC was not significant, p = 0.83, nor was the difference between HRnHER2p vs TNBC, p = 0.91. Distant disease or death from breast cancer was identified for 395 patients, 86 with HRp low-risk, 137 with HRp high-risk, 50 with HRpHERp, 69 with HRnHER2p, and 53 with TNBC. Iraqi HRpHER2n BCs can be separated into low and high risk using the Magee 2 risk assessment equation. The HRp low-risk BC has a favorable outcome. HRp high-risk was the most common subtype and the major cause of recurrent distant disease.
Indexed as
Identifiers
41774182What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.